Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Priebe

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Biochemistry|July 22, 1997
Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopyH Robinson, W Priebe, J B Chaires, et al.
International Journal of Cancer|May 4, 1995
Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cellsY H Ling, Y Zou, W Priebe, et al.
Anti-Cancer Drugs|February 1, 1993
Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicityW Priebe, N T Van, T G Burke, et al.
Acta Biochimica Polonica|August 29, 2000
A simple model for predicting the free energy of binding between anthracycline antibiotics and DNAW R Rudnicki, M Kurzepa, T Szczepanik, et al.
European Journal of Biochemistry|November 1, 1996
The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipidsL Gallois, M Fiallo, A Laigle, et al.
Journal of the National Cancer Institute|November 1, 1995
How does the MRP/GS-X pump export doxorubicin?T Ishikawa, K Akimaru, M T Kuo, et al.
Drug Design and Delivery|June 1, 1990
4-Demethoxy-3'-N-trifluoroacetyldoxorubicin. Synthesis and solid tumor activityD Horton, W Priebe, J P Carter, et al.
Anticancer Research|September 1, 1994
Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicinJ Y Zhao, N Savaraj, R Song, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2000
Allosteric, chiral-selective drug binding to DNAX Qu, J O Trent, I Fokt, et al.
International Journal of Cancer|May 29, 1995
Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomesY Zou, Y H Ling, S Reddy, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Biochemistry|July 22, 1997
Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopyH Robinson, W Priebe, J B Chaires, et al.
International Journal of Cancer|May 4, 1995
Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cellsY H Ling, Y Zou, W Priebe, et al.
Anti-Cancer Drugs|February 1, 1993
Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicityW Priebe, N T Van, T G Burke, et al.
Acta Biochimica Polonica|August 29, 2000
A simple model for predicting the free energy of binding between anthracycline antibiotics and DNAW R Rudnicki, M Kurzepa, T Szczepanik, et al.
European Journal of Biochemistry|November 1, 1996
The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipidsL Gallois, M Fiallo, A Laigle, et al.
Journal of the National Cancer Institute|November 1, 1995
How does the MRP/GS-X pump export doxorubicin?T Ishikawa, K Akimaru, M T Kuo, et al.
Drug Design and Delivery|June 1, 1990
4-Demethoxy-3'-N-trifluoroacetyldoxorubicin. Synthesis and solid tumor activityD Horton, W Priebe, J P Carter, et al.
Anticancer Research|September 1, 1994
Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicinJ Y Zhao, N Savaraj, R Song, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2000
Allosteric, chiral-selective drug binding to DNAX Qu, J O Trent, I Fokt, et al.
International Journal of Cancer|May 29, 1995
Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomesY Zou, Y H Ling, S Reddy, et al.
Pageof 9